Shares of Lockheed Martin (LMT) are up 17 percent year-to-date and over 220 percent in the past five years. The defense giant is certainly flying high - and cranking out cash - as a result of escalating global tensions, says John Augustine, chief investment officer at Huntington National Bank (HBAN) . 'They keep generating cash flows to return to shareholders, plus they have the F-35 program,' said Augustine. Augustine added that defense stocks will continue to be in favor, but they are 'not in the political spotlight' which is keeping them from being overblown. Augustine is also bullish on Johnson & Johnson (JNJ) , which has seen its stock rise 20 percent so far in 2016. The healthcare giant has been popular with investors this year due to its three percent dividend yield. Nevertheless, Augustine is particularly enamored with the stock due to its oncology pipeline. 'Both our groups like it, blue chip core and blue chip dividend,' said Augustine. 'It's one that our customers can play for total return or income.' Speaking of income, Augustine is a fan of Realty Income (O) , primarily for its 3.4 percent dividend yield in this income starved world. The REIT is up 36 percent year-to-date, far outperforming the 12 percent return of the iShares U.S. Real Estate ETF (IYR) .
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.